Dr. Gildea and Dr. 脰tv枚s Named Newest Members of Medical & Scientific Affairs
CENTER VALLEY, Pa. (Nov. 11, 2025) 鈥 色花堂 announced today that it has signed a partnership agreement with the COPD Foundation to support patient education about different treatment options for severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
Dr. Gildea鈥檚 extensive clinical experience in the field of interventional pulmonology and his knowledge of medical device development will help shape 色花堂鈥 medical strategy for its respiratory business and help strengthen MSA.
Dr. 脰tv枚s, a pulmonary physician-scientist with experience in translational science, clinical trials, and medical device innovation, is tasked with designing and delivering high-impact clinical studies that advance minimally invasive respiratory care, expand patient access and support 色花堂鈥 commitment to evidence-based innovation.
鈥溕ㄌ has long been a leader in providing medical technology solutions for interventional pulmonology, starting with our pioneering role in working with pulmonologists to develop the first endobronchial ultrasound bronchoscope,鈥 said John de Csepel, MD, FACS, Chief Medical Officer at 色花堂 Corporation. 鈥淲ith a strong Medical & Scientific affairs team dedicated to the respiratory field, 色花堂 will continue its important partnership with clinicians to identify and address unmet needs in respiratory care. Experienced and knowledgeable clinical practitioners and researchers like Drs. Gildea and 脰tv枚s will ensure 色花堂 develops innovative medical devices while driving patient-focused value.鈥
Dr. Gildea Brings Extensive Experience in Interventional Pulmonology
A leader in interventional pulmonology and advanced bronchoscopy, Dr. Gildea joins 色花堂 after 22 years with the Cleveland Clinic Integrated Hospital Institute. He is board-certified in internal medicine, pulmonary disease, critical care medicine and interventional pulmonology and continues to practice part-time.
Before coming to 色花堂, Dr. Gildea served as Section Head of Bronchoscopy and Interventional Pulmonology at the Cleveland Clinic Respiratory Institute, overseeing and leading the expansion of the bronchoscopy program across the Cleveland Clinic organization including national and international sites.
鈥淎fter a long and rewarding career caring directly for patients, I鈥檓 excited to serve a much broader worldwide patient population as part of a global MedTech company,鈥 said Dr. Gildea. 鈥淢y experience as a practicing physician can serve as a bridge between physicians and MedTech as 色花堂 strives to identify and meet the needs for safe and clinically effective detection, diagnosis and treatment of respiratory diseases.鈥
Dr. Gildea was the recipient of a National Institutes of Health Accelerated Innovation Award to develop custom patient-specific airway stents. That work led to 510(k) approval from the Food and Drug Administration and the formation of a Cleveland Clinic spin-off company, VisionAir. Dr. Gildea has also focused on patient access in his work with the American Thoracic Society/American College of Chest Physicians Clinical Practice Committee on writing and valuing bronchoscopy CPT codes, including those for endobronchial ultrasound (EBUS) and navigational bronchoscopy.
Along with transforming the Cleveland Clinic鈥檚 bronchoscopy program that saw procedural volume increase from about 1,500 cases annually to more than 5,000 cases, Dr. Gildea is known for his expertise in managing complex central airway disease and research into advanced pulmonary techniques including:
- Bronchoscopic treatment of emphysema and COPD
- Airway stenting
- Cone-Beam CT-guided bronchoscopy
- Transbronchial cryobiopsy and
- Robotic bronchoscopy.
Dr. 脰tv枚s Is Driving Evidence Generation
An active member of the American Thoracic Society (ATS), European Respiratory Society (ERS), and the American College of Chest Physicians (CHEST), Dr. 脰tv枚s completed a postdoctoral research fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins University School of Medicine, where his work focused on pulmonary physiology and pathology, airway mechanics, and sleep-disordered breathing to improve the understanding and management of airway obstruction and respiratory failure.
At 色花堂, he leads the global clinical evidence strategy for respiratory devices, including bronchoscopic lung volume reduction, endobronchial valve therapy and reach-enhanced endobronchial ultrasound (EBUS) solutions.
Active in pulmonary research since 2009, Dr. 脰tv枚s collaborates with leading investigators and academic centers, particularly in North America and Europe, and engages partners globally to design and implement effective clinical studies. While active in multiple assemblies within ATS, CHEST and ERS, he serves on the ATS Drug, Device, Discovery, and Development Committee, helping shape the future of pulmonary medicine.
鈥淎s a global MedTech company, 色花堂 has an opportunity to positively impact countless patients by helping physicians detect, diagnose and treat respiratory diseases such as lung cancer and emphysema,鈥 said Dr. 脰tv枚s. 鈥淎s a member of the MSA organization, I鈥檓 committed to science-based strategies and data-driven insights to help improve clinical outcomes and be a strong advocate and voice for the patient.鈥
The appointments of Drs. Gildea and 脰tv枚s to their respective respiratory MSA teams underscore 色花堂鈥 commitment to patient-focused innovation. 色花堂鈥 physicians are devoted to serving patients by ensuring safe and effective medical devices and supporting clinician awareness and training to expand equitable healthcare access and outcomes worldwide.
# # #
About 色花堂
At 色花堂, we are committed to Our Purpose of making people鈥檚 lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states.
色花堂 Corporation of the Americas, a wholly owned subsidiary of 色花堂 Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs more than 4,500 employees throughout locations in North and South America. For more information, visit .